Your browser doesn't support javascript.
Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA.2.
Uraki, Ryuta; Kiso, Maki; Iida, Shun; Imai, Masaki; Takashita, Emi; Kuroda, Makoto; Halfmann, Peter J; Loeber, Samantha; Maemura, Tadashi; Yamayoshi, Seiya; Fujisaki, Seiichiro; Wang, Zhongde; Ito, Mutsumi; Ujie, Michiko; Iwatsuki-Horimoto, Kiyoko; Furusawa, Yuri; Wright, Ryan; Chong, Zhenlu; Ozono, Seiya; Yasuhara, Atsuhiro; Ueki, Hiroshi; Sakai-Tagawa, Yuko; Li, Rong; Liu, Yanan; Larson, Deanna; Koga, Michiko; Tsutsumi, Takeya; Adachi, Eisuke; Saito, Makoto; Yamamoto, Shinya; Hagihara, Masao; Mitamura, Keiko; Sato, Tetsuro; Hojo, Masayuki; Hattori, Shin-Ichiro; Maeda, Kenji; Valdez, Riccardo; Okuda, Moe; Murakami, Jurika; Duong, Calvin; Godbole, Sucheta; Douek, Daniel C; Maeda, Ken; Watanabe, Shinji; Gordon, Aubree; Ohmagari, Norio; Yotsuyanagi, Hiroshi; Diamond, Michael S; Hasegawa, Hideki; Mitsuya, Hiroaki.
  • Uraki R; Division of Virology, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
  • Kiso M; The Research Center for Global Viral Diseases, National Center for Global Health and Medicine Research Institute, Tokyo, Japan.
  • Iida S; Division of Virology, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
  • Imai M; Department of Pathology, National Institute of Infectious Diseases, Tokyo, Japan.
  • Takashita E; Division of Virology, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
  • Kuroda M; The Research Center for Global Viral Diseases, National Center for Global Health and Medicine Research Institute, Tokyo, Japan.
  • Halfmann PJ; Center for Influenza and Respiratory Virus Research, National Institute of Infectious Diseases, Tokyo, Japan.
  • Loeber S; Influenza Research Institute, Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI, USA.
  • Maemura T; Influenza Research Institute, Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI, USA.
  • Yamayoshi S; Department of Surgical Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI, USA.
  • Fujisaki S; Influenza Research Institute, Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI, USA.
  • Wang Z; Division of Virology, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
  • Ito M; The Research Center for Global Viral Diseases, National Center for Global Health and Medicine Research Institute, Tokyo, Japan.
  • Ujie M; Center for Influenza and Respiratory Virus Research, National Institute of Infectious Diseases, Tokyo, Japan.
  • Iwatsuki-Horimoto K; Department of Animal Dairy, and Veterinary Sciences, College of Agriculture and Applied Sciences, Utah State University, Logan, UT, USA.
  • Furusawa Y; Division of Virology, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
  • Wright R; Division of Virology, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
  • Chong Z; The Research Center for Global Viral Diseases, National Center for Global Health and Medicine Research Institute, Tokyo, Japan.
  • Ozono S; Division of Virology, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
  • Yasuhara A; Division of Virology, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
  • Ueki H; The Research Center for Global Viral Diseases, National Center for Global Health and Medicine Research Institute, Tokyo, Japan.
  • Sakai-Tagawa Y; Laboratory of Ultrastructural Virology, Institute for Frontier Life and Medical Sciences, Kyoto University, Kyoto, Japan.
  • Li R; Influenza Research Institute, Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI, USA.
  • Liu Y; Department of Medicine, Washington University School of Medicine, St Louis, MO, USA.
  • Larson D; Department of Pathology, National Institute of Infectious Diseases, Tokyo, Japan.
  • Koga M; Division of Virology, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
  • Tsutsumi T; Division of Virology, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
  • Adachi E; The Research Center for Global Viral Diseases, National Center for Global Health and Medicine Research Institute, Tokyo, Japan.
  • Saito M; Division of Virology, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
  • Yamamoto S; Department of Animal Dairy, and Veterinary Sciences, College of Agriculture and Applied Sciences, Utah State University, Logan, UT, USA.
  • Hagihara M; Department of Animal Dairy, and Veterinary Sciences, College of Agriculture and Applied Sciences, Utah State University, Logan, UT, USA.
  • Mitamura K; Department of Animal Dairy, and Veterinary Sciences, College of Agriculture and Applied Sciences, Utah State University, Logan, UT, USA.
  • Sato T; Division of Infectious Diseases, Advanced Clinical Research Center, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
  • Hojo M; Department of Infectious Diseases and Applied Immunology, IMSUT Hospital of The Institute of Medical Science, University of Tokyo, Tokyo, Japan.
  • Hattori SI; Division of Infectious Diseases, Advanced Clinical Research Center, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
  • Maeda K; Department of Infectious Diseases and Applied Immunology, IMSUT Hospital of The Institute of Medical Science, University of Tokyo, Tokyo, Japan.
  • Valdez R; Department of Infectious Diseases and Applied Immunology, IMSUT Hospital of The Institute of Medical Science, University of Tokyo, Tokyo, Japan.
  • Okuda M; Department of Infectious Diseases and Applied Immunology, IMSUT Hospital of The Institute of Medical Science, University of Tokyo, Tokyo, Japan.
  • Murakami J; Division of Virology, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
  • Duong C; Division of Infectious Diseases, Advanced Clinical Research Center, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
  • Godbole S; Department of Hematology, Eiju General Hospital, Tokyo, Japan.
  • Douek DC; Division of Infection Control, Eiju General Hospital, Tokyo, Japan.
  • Maeda K; Disease Control and Prevention Center, National Center for Global Health and Medicine Hospital, Tokyo, Japan.
  • Watanabe S; Department of Respiratory Medicine, National Center for Global Health and Medicine Hospital, Tokyo, Japan.
  • Gordon A; Department of Refractory Viral Infections, National Center for Global Health and Medicine Research Institute, Tokyo, Japan.
  • Ohmagari N; Department of Refractory Viral Infections, National Center for Global Health and Medicine Research Institute, Tokyo, Japan.
  • Yotsuyanagi H; Department of Pathology, University of Michigan, Ann Arbor, MI, USA.
  • Hasegawa H; Division of Virology, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
  • Mitsuya H; Division of Virology, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
Nature ; 607(7917): 119-127, 2022 07.
Article in English | MEDLINE | ID: covidwho-1915276
ABSTRACT
The recent emergence of SARS-CoV-2 Omicron (B.1.1.529 lineage) variants possessing numerous mutations has raised concerns of decreased effectiveness of current vaccines, therapeutic monoclonal antibodies and antiviral drugs for COVID-19 against these variants1,2. The original Omicron lineage, BA.1, prevailed in many countries, but more recently, BA.2 has become dominant in at least 68 countries3. Here we evaluated the replicative ability and pathogenicity of authentic infectious BA.2 isolates in immunocompetent and human ACE2-expressing mice and hamsters. In contrast to recent data with chimeric, recombinant SARS-CoV-2 strains expressing the spike proteins of BA.1 and BA.2 on an ancestral WK-521 backbone4, we observed similar infectivity and pathogenicity in mice and hamsters for BA.2 and BA.1, and less pathogenicity compared with early SARS-CoV-2 strains. We also observed a marked and significant reduction in the neutralizing activity of plasma from individuals who had recovered from COVID-19 and vaccine recipients against BA.2 compared to ancestral and Delta variant strains. In addition, we found that some therapeutic monoclonal antibodies (REGN10987 plus REGN10933, COV2-2196 plus COV2-2130, and S309) and antiviral drugs (molnupiravir, nirmatrelvir and S-217622) can restrict viral infection in the respiratory organs of BA.2-infected hamsters. These findings suggest that the replication and pathogenicity of BA.2 is similar to that of BA.1 in rodents and that several therapeutic monoclonal antibodies and antiviral compounds are effective against Omicron BA.2 variants.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / SARS-CoV-2 / COVID-19 Drug Treatment Type of study: Experimental Studies Topics: Vaccines / Variants Limits: Animals Language: English Journal: Nature Year: 2022 Document Type: Article Affiliation country: S41586-022-04856-1

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / SARS-CoV-2 / COVID-19 Drug Treatment Type of study: Experimental Studies Topics: Vaccines / Variants Limits: Animals Language: English Journal: Nature Year: 2022 Document Type: Article Affiliation country: S41586-022-04856-1